Taken together, this study indicates that a subset of lethal prostate cancers exhibit MMRd at diagnosis, that different assay methods can yield different diagnoses, and that only a proportion of diagnosed advanced prostate cancers have corresponding high TMB and stain with PD-L1 IHC. This evidence concerns the gene CD274 and Familial prostate cancer.